Brief: Avacta Announces US FDA Clearance Of The Investigational New Drug Application For The Second pre|CISION Medicine, FAP-Exatecan
21/01/2026 13:05
Jan 21 (Reuters) - Avacta Group PLC AVCT.L: AVACTA ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION CLEARANCE OF THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR THE SECOND PRE|CISION® MEDICINE, FAP-EXATECAN (AVA6103) AVACTA THERAPEUTICS: PHASE 1 CLINICAL STUDY OF FAP-EXD (AVA6103) IS ANTICIPATED TO BEGIN LATER IN Q1 2026 Source text: ID:nGNX3CQ6SM Further company coverage: AVCT.L ((Reuters.Briefs@thomsonreuters.com;))